Copiktra
Payments companies reported to CMS as associated with Copiktra. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Copiktra, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Copiktra
These are the largest totals companies reported as associated with Copiktra. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| David Sidransky | Baltimore, MD | Medical Oncology | $312,787.00 |
| Ryan Jacobs | Charlotte, NC | Hematology (Internal Medicine) | $68,936.19 |
| Mojtaba Akhtari | Omaha, NE | Hematology & Oncology | $29,568.97 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $10,952.32 |
| Javier Pinilla-Ibarz | Tampa, FL | Hematology (Internal Medicine) | $9,869.24 |
| Mohamad Cherry | Morristown, NJ | Hematology & Oncology | $9,610.15 |
| Matthew Cortese | Buffalo, NY | Hematology & Oncology | $3,415.00 |
| Jodie Delesio | Newark, DE | Family | $3,226.85 |
| Salvia Jain | Boston, MA | Hematology (Internal Medicine) | $2,175.71 |
| Stefan Gluck | Miami, FL | Hematology & Oncology | $1,650.00 |
Prescribed Copiktra?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.